Image For Activity Cover
LQCL2413 - CMLE - MUTYH-Associated Polyposis Syndrome Identified by Tumor Marker Panel Testing
Course Description

LabQ 2024 Clinical Laboratory: Molecular Diagnostics 

Faculty/Authors

Delecia R. Robinson, MD
Senior Medical Director, Laboratory Medicine (Molecular and Non-molecular)
eviCore Healthcare
Bluffton, South Carolina 

CMLE Credit: 2.0
Estimated Completion Time: 2 hour
Format: Online Educational Activity and Post Exam

Default Credit Type: None (You must meet the eligibility requirements in order to obtain CME or SAMs CME credit.)

Instructions

To claim CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Course to view an overview of the modules in this course.
  3. Click Access to begin the course.
  4. Review the Educational Activity.
  5. Complete and submit the Post Exam.
  6. Submit the course Evaluation to register your credit.

Faculty Disclosures​
The Journal CME editor and faculty have no relevant financial relationships with commercial interests to disclose.

Technical Considerations

Release Date:  03/31/2024
Review Date:
Expiration Date: 12/31/2026 

Course Objectives
Following completion of this activity, you will be able to:
  • briefly describe the workflow for next-generation sequencing of paraffin-embedded tumor samples; 

  • list several tumor mutations and the associated drug class that may (or may not) be used to treat them; 

  • contrast the clinical implications of monoallelic and biallelic MUTYH mutations;

  • describe the testing required to determine if a mutation identified by a next-generation sequencing tumor marker panel is a germline mutation; and  

  • discuss the increased cancer risks associated with MUTYH-associated polyposis hereditary cancer syndrome.  

Summary
Availability: On-Demand
Credit Offered:
2 CMLE Credits
Powered By